{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:10Z","timestamp":1792528270006,"version":"4.5.0"},"reference-count":56,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety and efficacy of deucravacitinib through 4\u2009years in the Phase 3 POETYK PSO\u20101, PSO\u20102 and long\u2010term extension (LTE) trials in psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PSO\u20101 and PSO\u20102 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6\u2009mg once daily (QD) or apremilast 30\u2009mg twice daily. At 52\u2009weeks, patients enrolled in the LTE trial received open\u2010label deucravacitinib 6\u2009mg QD. Safety was evaluated in patients who received \u22651 dose of deucravacitinib at any time. Clinical and patient\u2010reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 1519 patients received \u22651 dose of deucravacitinib, with cumulative exposure of 4392.8 person\u2010years (PY) through the data cut\u2010off of 1 November 2023. Exposure\u2010adjusted incidence rates (EAIRs)\/100 PY of noted safety measures were comparable or decreased from the 1\u2010year to 4\u2010year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID\u201019) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib (<jats:italic>n<\/jats:italic>\u2009=\u2009513), clinical and patient\u2010reported outcome rates were well maintained from 1\u2009year through 4\u2009years (e.g. PASI 90, 1\u2009year, 45.6% [95% CI, 41.3%\u201350.0%], 4\u2009years, 47.5% [42.6%\u201352.4%]; DLQI 0\/1, 1\u2009year, 51.5% [47.1%\u201355.9%], 4\u2009years, 49.4% [44.4%\u201354.4%]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4\u2009years of treatment in patients with moderate to severe plaque psoriasis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.20553","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:25:01Z","timestamp":1741713901000},"page":"1336-1351","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Deucravacitinib in plaque psoriasis: Four\u2010year safety and efficacy results from the Phase 3 <scp>POETYK PSO<\/scp>\u20101, <scp>PSO<\/scp>\u20102 and long\u2010term extension trials"],"prefix":"10.1111","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[{"name":"University of California Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre Northern Care Alliance NHS Foundation Trust  Manchester UK"},{"name":"NIHR Manchester Biomedical Research Centre Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[{"name":"University of California Los Angeles  Los Angeles California USA"},{"name":"Dermatology Research Associates  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Paul Sabatier University and CHU Larrey  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research, Waterloo, and the University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5653-381X","authenticated-orcid":false,"given":"Matthew J.","family":"Colombo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7910-1668","authenticated-orcid":false,"given":"Julie","family":"Scotto","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vritzali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Berger","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgene","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1365-5207","authenticated-orcid":false,"given":"Subhashis","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute and Comprehensive Center for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, and Central Connecticut Dermatology Research  Cromwell Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw1736"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_13_4_1","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"e_1_2_13_5_1","volume-title":"Sotyktu [European summary of product characteristics]","year":"2023"},{"key":"e_1_2_13_6_1","volume-title":"Sotyktu [package insert]","year":"2022"},{"key":"e_1_2_13_7_1","volume-title":"Sotyktu [product information]","year":"2022"},{"key":"e_1_2_13_8_1","volume-title":"Sotyktu [product monograph]","year":"2022"},{"key":"e_1_2_13_9_1","volume-title":"Sotyktu [UK summary of product characteristics]","year":"2024"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae014"},{"key":"e_1_2_13_14_1","unstructured":"ArmstrongA LebwohlM WarrenRB SofenH ImafukuS OhtsukiM et\u00a0al.Deucravacitinib in plaque psoriasis: 3\u2010year safety and efficacy results from the phase 3 POETYK PSO 1 and PSO 2 trials [oral presentation FC.02.7]. Presented at: Annual Congress of the European Academy of Dermatology and Venereology; 11\u201014 October 2023; Berlin Germany."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12214"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.11.004"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1024"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.10.005"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"issue":"10","key":"e_1_2_13_22_1","first-page":"S690","article-title":"Malignancies in the psoriasis longitudinal assessment and registry study: cumulative experience [abstract 1563]","volume":"66","author":"Fiorentino D","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_13_23_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp K","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-015-1593-8"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216102"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.1121"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14068"},{"key":"e_1_2_13_28_1","unstructured":"Surveillance Research Program National Cancer Institute.Seer*Explorer: an interactive website for SEER cancer statistics [Internet].2023."},{"key":"e_1_2_13_29_1","volume-title":"Cosentyx (secukinumab) assessment report","year":"2014"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15723"},{"key":"e_1_2_13_31_1","volume-title":"Skyrizi CHMP assessment report","year":"2019"},{"key":"e_1_2_13_32_1","unstructured":"U.S. Food and Drug Administration.Tremfya (guselkumab) BLA multi\u2010disciplinary review and evaluation.2016."},{"key":"e_1_2_13_33_1","volume-title":"Stelara (ustekinumab) assessment report","year":"2009"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.6.719"},{"key":"e_1_2_13_35_1","volume-title":"Humira (adalimumab) scientific discussion","year":"2007"},{"key":"e_1_2_13_36_1","volume-title":"Cimzia (certolizumab pegol) assessment report","year":"2018"},{"key":"e_1_2_13_37_1","unstructured":"U.S. Food and Drug Administration.Siliq (brodalumab) BLA.2015."},{"key":"e_1_2_13_38_1","volume-title":"Ilumetri (tildrakizumab) assessment report","year":"2018"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S239511"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1942974"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018125"},{"key":"e_1_2_13_43_1","first-page":"S376","article-title":"Overview of venous thromboembolism","volume":"23","author":"Phillippe HM","year":"2017","journal-title":"Am J Manag Care"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03986.x"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0024"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4847"},{"key":"e_1_2_13_47_1","volume-title":"Cancer facts & figures","year":"2020"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0337-2"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12165"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2015.1115586"},{"key":"e_1_2_13_51_1","volume-title":"Global cancer observatory: cancer today","author":"Ferlay J","year":"2021"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000187"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.5070\/D32410041706"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.23"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16332"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.028"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T08:25:26Z","timestamp":1760689526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":56,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/jdv.20553"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20553","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"2024-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}